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Although transvenous pacemakers and implantable
cardioverter-deﬁbrillators (ICD) have long been the standard
of care, they are not without signiﬁcant drawbacks. In recent
years, major advances have been achieved in leadless pace-
maker technology1 and entirely subcutaneous ICD (S-ICD)
systems2 that obviate intracardiac leads and hence carry
the potential to reduce associated complications. Unlike
standard ICDs, the S-ICD is devoid of antibradycardia
pacing capabilities. Nevertheless, certain patients, such as
those lacking vascular access for transvenous lead insertion,
may beneﬁt from leadless devices with both pacing and
ICD functions. Herein, we present the ﬁrst patient in
whom the leadless pacemaker and S-ICD were used in
combination.Case presentation
A 70-year-old man with coronary artery disease, mechanical
prosthetic aortic and mitral valves, permanent atrial ﬁbrilla-
tion, and a left ventricular ejection fraction of 30% was
referred to our institution for a primary prevention ICD.
He was on long-term dialysis therapy via a catheter tunneled
to the right internal jugular vein. On preprocedural venog-
raphy, complete obstruction of the left subclavian vein was
noted along with severe stenosis of the right subclavian vein.
In the absence of pacemaker indications, the patient was
further assessed for an S-ICD. During the screening test,
T-wave oversensing was registered with the subcutaneousKEYWORDS Subcutaneous deﬁbrillator; Leadless pacemaker; Venous throm-
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defibrillator; VF ¼ ventricular fibrillation
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).lead positioned along the left sternal border. However, no
such T-wave oversensing occurred with the lead to the right
of the sternum. An S-ICD (Model SQRX; Boston Scientiﬁc,
Malborough, MA) was therefore implanted under general
anesthesia, with the can placed in a left lateral position over
the ﬁfth and sixth intercostal space. The deﬁbrillation lead
was tunneled towards the xiphoid process and then cranially
to the right of the sternum. Ventricular ﬁbrillation (VF) was
induced and a 65 J shock effectively restored sinus rhythm.
The procedure was well tolerated and without complication.
Seventeen months later, the patient presented to the
emergency room with syncope and complete atrioventricular
block. A temporary pacemaker was placed by means of a
right-sided femoral approach. In light of the vascular access
constraints, a leadless pacemaker (Nanostim system; St Jude
Medical St. Paul, MN) was then inserted with an 18F
introducer in the right femoral vein and implanted at the
apex of the right ventricle. The threshold was 2 V at 0.4 ms,
R-wave 7 mV, and lead impedance 960 ohm. As displayed in
Figure 1, during testing the pacemaker was programmed at
maximum output (6.5 V @ 0.5 ms) and no oversensing or
double counting was detected by the S-ICD in all 3 con-
ﬁgurations (primary, secondary, alternate). The programmed
automatic conﬁguration was therefore retained. Although VF
was not re-induced, an 80 J shock was delivered by the S-
ICD on QRS timing, which did not result in mode reversion,
shutdown, or dislodgment of the pacemaker. Moreover, no
noise (ie, from modulated pacing pulses) was perceived by
the S-ICD during pacemaker interrogation and programming
(Figure 2). The chest radiograph in Figure 3 shows the
position of the S-ICD and leadless pacemaker in anteropos-
terior and lateral views. At 6 months of follow-up, the
patient's evolution continues to be uneventful, with 12%
ventricular pacing (0.5 V at 0.4 ms, R-wave 12 mV, and
lead impedance 540 ohm), no recurrent syncope, and no
S-ICD shock.Discussion
To our knowledge, this is the ﬁrst case reported of a leadless
pacemaker implanted in combination with an S-ICD. A few
prior reports have described S-ICD systems in patients withpen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.07.009
KEY TEACHING POINTS
 A subcutaneous implantable cardioverter-
deﬁbrillator may potentially be used in
combination with a leadless pacemaker.
 Some careful attention must be brought to device
interaction.
 This strategy carries the potential of pacing and
deﬁbrillation for patients in whom standard
transvenous approaches are not feasible or
desirable.
Heart Rhythm Case Reports, Vol 1, No 6, November 2015470transvenous and epicardial pacemakers.3,4 When these 2
technologies are used together, pacemakers must be pro-
grammed to stimulate in a bipolar mode in order to avoid
double counting by the S-ICD. Functionally, a leadless
pacemaker operates in a fashion similar to a standard bipolar
VVIR pacemaker. Even when programmed to maximum
output, no oversensing was detected by the S-ICD. InFigure 1 Subcutaneous implantable cardioverter-deﬁbrillator electrogram rec
maximum output (6.5 V@ 0.5 ms) pacing (right) are shown in the following 3 conﬁ
conﬁguration.addition, we were concerned over the potential for leadless
pacemaker dysfunction after delivery of an S-ICD shock.
We therefore tested this scenario by delivering a maximum-
output shock from the S-ICD. No device interactions were
noted, as the leadless pacemaker continued to function as
programmed during and after the shock. Since VF was not
re-induced after pacemaker implantation, we could not
exclude the possibility that VF undersensing by the pace-
maker may lead to pacing spikes that are more prominently
seen by the S-ICD, as its detection algorithm ﬁlters out ﬁner
subcutaneous electrocardiographic signals.
In conclusion, our case demonstrates that an S-ICD may
potentially be used in combination with a leadless pacemaker
to provide pacing and ICD functions without intracardiac
leads. However, given that unexpected behavior may occur
during VF, electromagnetic interference, or sensing vector
changes, a more formal safety assessment with regard to
possible device interactions is required before widespread
adoption. This combined leadless strategy carries the poten-
tial to widen our therapeutic armamentarium for patients who
have indications for pacemakers and ICDs but in whomordings during spontaneous sinus rhythm (left) and during VVI 90 bpm
gurations:A: primary conﬁguration;B: secondary conﬁguration;C: alternate
Figure 2 Recordings during interrogation and programming of the leadless pacemaker. A: A 12-lead electrocardiographic recording showing the absence of
noise from modulated pacing pulses. B: Subcutaneous implantable cardioverter-deﬁbrillator recordings in primary (upper panel), secondary (middle panel), and
alternate (lower panel) conﬁgurations during interrogation and programming of the leadless pacemaker, likewise demonstrating the absence of detected
interference.
Figure 3 Chest radiograph. Shown are anteroposterior and lateral views of the leadless pacemaker (PM) and subcutaneous implantable cardioverter-
deﬁbrillator (S-ICD) systems.
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